The frequency of change in five-point scale score with a Bayesian penalised likelihood PET reconstruction algorithm on interim FDG PET-CT and its potential implications for therapy decisions in Hodgkin's lymphoma.
Humans
Positron Emission Tomography Computed Tomography
Hodgkin Disease
/ diagnostic imaging
Fluorodeoxyglucose F18
Bayes Theorem
Antineoplastic Combined Chemotherapy Protocols
Radiopharmaceuticals
Doxorubicin
/ therapeutic use
Bleomycin
/ therapeutic use
Dacarbazine
/ therapeutic use
Vinblastine
/ therapeutic use
Algorithms
Positron-Emission Tomography
/ methods
Journal
Clinical radiology
ISSN: 1365-229X
Titre abrégé: Clin Radiol
Pays: England
ID NLM: 1306016
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
21
07
2022
revised:
21
09
2022
accepted:
23
09
2022
pubmed:
5
11
2022
medline:
18
1
2023
entrez:
4
11
2022
Statut:
ppublish
Résumé
To assess the effect of a Bayesian penalised likelihood (BPL) reconstruction algorithm on the five-point scale (5-PS) score, response categorisation, and potential implications for therapy decisions after interim 2-[ The present study included new patients with HL undergoing iPET-CT from 2014-2019 after two cycles of doxorubicin (Adriamycin), bleomycin, vincristine, and dacarbazine (ABVD). Two reporters categorised response using the 5-PS and measured maximum standardised uptake values (SUV Eighty-one iPET-CT examinations were reviewed. Compared with OSEM, BPL increased the 5-PS score by a single score in 18/81 (22.2%) patients. The frequency of potential treatment intensification by changing a score of 3-4 was 13.6% (11/81) and represented 25% (11/44) of patients with a score of 3 on OSEM. All 11 patients remained in remission without a change in therapy (mean 63 months) except one who required second-line treatment for refractory disease. Median SUV BPL PET reconstruction increased the 5-PS score on iPET-CT in 22% of HL patients and can potentially result in unnecessary treatment escalation in over half of these patients.
Identifiants
pubmed: 36333130
pii: S0009-9260(22)00669-9
doi: 10.1016/j.crad.2022.09.124
pii:
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Radiopharmaceuticals
0
Doxorubicin
80168379AG
Bleomycin
11056-06-7
Dacarbazine
7GR28W0FJI
Vinblastine
5V9KLZ54CY
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e89-e98Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.